Caroline Tanner
Sunnyvale, CANPI 1043256035
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,141 of the $76,511 with a category attached, or 82.5%. 17 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 31.1% of the total. Reporting peaked in 2024 at $25,005 and has fallen 69.9% since, to $7,532 in 2025.
Across 65 payments — averaging $1177.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$24K
- Acorda Therapeutics, Inc$11K
- Jazz Pharmaceuticals Inc.$10K
- Genentech, Inc.$8K
- Genentech USA, Inc.$8K
- Amneal Pharmaceuticals LLC$4K
- plus $12K from 11 others
Across 281 payments — averaging $11,029 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- Roche TCRC, Inc.$1.2M
- Biogen$327K
- Neurocrine Biosciences, Inc.$3K
What the payments were for
- Consulting fees$63,14183%
- Speaking & faculty fees$6,2008%
- Travel & lodging$4,9306%
- Food & beverage$2,2403%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 10 | $23,825 |
| Acorda Therapeutics, Inc | 7 | $10,838 |
| Jazz Pharmaceuticals Inc. | 4 | $9,990 |
| Genentech, Inc. | 5 | $7,590 |
| Genentech USA, Inc. | 8 | $7,532 |
| Amneal Pharmaceuticals LLC | 5 | $4,459 |
| Kyowa Kirin Pharmaceutical Development, Inc | 2 | $4,000 |
| MDD US Operations, LLC | 4 | $3,622 |
| H. Lundbeck A S | 1 | $2,000 |
| Biogen | 3 | $1,561 |
| Medtronic(2 entities) | 5 | $497 |
| Boston Scientific | 4 | $180 |
| Adamas Pharmaceuticals, Inc. | 1 | $113 |
| Supernus Pharmaceuticals, Inc. | 2 | $112 |
| Eisai Inc. | 1 | $90 |
| Acadia Pharmaceuticals Inc | 1 | $64 |
| AbbVie | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $1,234 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 11 | $326 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.